Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013

Size: px
Start display at page:

Download "Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013"

Transcription

1 Oncology Treatment Trends and Implications for Future Drug Development In China Presented by Stephanie Hawthorne 16 April 2013

2 Economic development, demographic shift, regulatory environment change, industry structure evolution are the major forces driving a growing market China market growth drivers Industry Structure Economic Development 8% GDP growth Growing household income Demographic factors Aging population Changing disease pattern Regulatory environment Healthcare reform Increasing government investment ($125 B over five years) Increased investment from all players Accelerating new product launch Expand sales forces 2009: USD$ 32Bil Projected China Market Value 2014: USD$ 76-86Bil Source: Kantar Health analysis 1

3 The population in China greatly exceeds the current largest pharma markets The population of China is approximately 75% larger than the combined populations of the 7 countries that currently represent the largest pharmaceutical markets by sales Total Population, 2013 Millions 1,500 1, US, EU5, J China US FR DE IT ES UK Japan Source: U.S. Census Bureau Intercensal Estimates and International Data Base, Japan Statistics Bureau, Japan National Institute of Population and Social Security Research, Instituto Nacionale de Estadistica, National Institute of Population and Social Security Research 2

4 Despite the large total population, the cancer market is smaller than one might expect The incident cancer market in China is approximately 80% of the size of the G7 combined, and twice the size of the U.S. incident population The lack of comprehensive diagnosis of cancer, particularly in rural China, is most likely responsible for the apparently low incident rate Incident Cancer Population, Millions US, EU5, J China US FR DE IT ES UK Japan Source: Kantar Health, CancerMPact Patient Metrics, accessed March 15, 2013; China 2011 Cancer Registry Annual Report 3

5 The growing cancer population in China may be associated with an increase in key risk factors Cancer mortality in China has been increasing rapidly and continuously over the past thirty years, from 74.2 per 100,000 in the 1970s to per 100,000 in the 1990s and to per 100,000 in This trend suggests an increase in risk factors for cancer, such as an aging population, deterioration of the environment, and an increasing adoption of western lifestyles. Prevalence of Cancer Risk Factors, 2011/ % 60% 40% 20% 0% Smoking Drinking Overweight / Obese China US EU5 Japan Source: Kantar Health. March National Health and Wellness Survey, 2012 [US, China], 2011 [EU5]. Princeton, NJ. 4

6 Cancer is more than just a disease of the elderly, it has a meaningful impact on the entire community Treatment for cancer has a negative impact on workplace productivity, for the patient Separately, caregivers may also find their productivity significant impacted The increase in absenteeism and loss of productivity speaks to one of the non-clinical unmet needs of cancer Source: Kantar Health. March National Health and Wellness Survey, 2012 [China]. Princeton, NJ. 5

7 Variation exists in the types of cancer most commonly diagnosed by global region While cancers of the colorectal and lung are common worldwide, tumors such as gastric and liver cancers have a greater incidence in Asia Top 5 Breast Prostate NSCLC Colorectal Melanoma Top 5 Prostate Colorectal Breast NSCLC Bladder Top 5 Gastric Colorectal NSCLC Breast Prostate Top 5 NSCLC Gastric Colorectal Liver Esophagus These differences support alternative opportunities and priorities for new drug development in China Sources: Incidence Rating based on 2013 projections; Kantar Health, CancerMPact Patient Metrics, accessed March 15, 2013; China National Central Cancer Registry under the Ministry of Health,

8 Fewer established cancer screening programs also lead to more advanced stage disease at diagnosis The vast majority of prostate cancer patients in the US, EU5, or Japan will be diagnosed with Stage II disease, whereas in China the majority of patients are diagnosed with Stage III/IV disease While there are few patients diagnosed with Stage IV breast cancer globally, there is a greater shift toward being diagnosed with Stage II/III disease in China than in the US, EU5, or Japan Stage at Diagnosis, Prostate Cancer, 2013 Stage at Diagnosis, Breast Cancer, % 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% US EU5 Japan China 0% US EU5 Japan China Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV The shift toward late stage diagnoses in China increases the need to rely on drug therapy for patient management Source: Kantar Health, CancerMPact Patient Metrics / EpiDatabase, accessed March 15, 2013; Li, et al, Chin Med J,

9 Treatment of cancer varies globally, for a number of reasons Category Access (regulatory) Access (affordability) Influencers Providers Patients Market authorization Out-of-pocket health care expenditures shift choice to lowest cost alternative Cooperative groups promote different standards Cancer care delivered by different specialties Ethnic differences in genetics, disease shape local approaches Example TS-1: standard of care for gastric in Japan; recently approved in Europe and China, unavailable in the United States Drug lag for Avastin: standard of care for CRC in Europe, Japan, and United States for nearly 10 years; approved in China in 2010 Orchiectomy for prostate cancer in China: surgery is cheap, compared to high (and continuing) cost of hormone therapy Herceptin, Rituxan: utilization in China Tier 1 cities half of G7 Hodgkin s: BEACOPP developed by German HLSG Myeloma: IFM favors Velcade, ECOG favors Revlimid Surgeons or Medical Oncologists: surgeons administer chemotherapy in Japan and favor low-toxicity, oral drugs Hospital systems in Tier 1 cities in China similar to the United States with chemotherapy departments Iressa in NSCLC: toehold in China and Japan, due to higher background rate of sensitizing EGFR somatic mutations Lower doses of cisplatin and taxanes utilized in China due to different metabolism related to pharmacogenomic differences 8

10 Key differences in the treatment of prostate cancer in China compared with the G7 In China, orchiectomy continues to be used as a means of testosterone deprivation in early-stage prostate cancer patients, in contrast to the (near universal) medical / chemical castration practiced in G7. Cost is likely the driver for the patients who receive it, as surgery is cheap compared to the higher, continuing costs of hormone therapy. Treatment of Non-metastatic Prostate Cancer, 2011/2012 Japan EU5 US China 0% 20% 40% 60% 80% 100% CAB LHRH analog only Orchiectomy only Other Notes: CAB, complete androgen blockade; LHRH, leutenizing hormone-releasing hormone Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 9

11 Key differences in the treatment of hepatocellular carcinoma in China compared with the G7 Treatment of locally-advanced HCC in China tends to rely more on the use of localized treatment options (i.e., TACE, RFA, HAI) similar to practices in Japan, whereas systemic therapy is more highly utilized in the US and EU Modality Treatment Approaches, Stage III / BCLC-C HCC, % 40.0% 20.0% 0.0% TACE alone Total TACE Total Surgery Total Localized therapy China US EU5 J Chemo alone Notes: TACE, transarterial chemoembolization; RFA, radiofrequency ablation; HAI, hepatic arterial infusion Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 10

12 Key differences in the treatment of breast cancer in China compared with the G7 In early-stage patients, there is a higher use of Breast Conserving Surgery (BCS) without radiotherapy in China, potentially due to the higher cost of radiation therapy compared with generic chemotherapy, despite strong clinical data supporting improved disease-free survival when RT is utilized following BCS Treatment of Stage I-II Breast Cancer, 2012 Japan EU5 US China 0% 20% 40% 60% 80% 100% BCS BCS plus RT Mastectomy Mastectomy plus RT Minimally invasive procedure Other surgical procedure Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 11

13 Key differences in the treatment of breast cancer in China compared with the G7, continued In recent years, the HER2 testing rate in breast cancer has grown greatly, with only half of breast cancer patients being tested in 2008 compared to 91% testing rate in The increased adoption of HER2 testing can be attributed to increased awareness of the test and coverage under the insurance schema. In 2009, there was a national program National HER2 Testing Quality Certification, sponsored by the Pathologic Society of China (PSA) with the goal of more accuracy of cancer testing Despite the standardization of HER2 testing, Herceptin use still lags HER2 Testing, Breast Cancer, China Use of Herceptin, HER2+ Breast Cancer, % 100% 80% 80% 60% 60% 40% 40% 20% 20% % Adjuvant 1L 2L China US EU5 Japan Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 12

14 Drug therapy coverage is largely dictated by the National Reimbursement Drug List (NRDL) Class A covered drugs are 100% reimbursed by the national healthcare system, and generally tend to be generic drugs Class B drug reimbursement is determined regionally and is typically 30% to 70% of cost; these tend to be newer chemotherapeutics or targeted agents, but often excluded premium priced drugs Some drugs may be covered on a Provincial Reimbursement Drug List Agent Not on NRDL NRDL Class A NRDL Class B 5-FU X Avastin X carboplatin X docetaxel X Erbitux X gemcitabine X Herceptin X Iressa X MabThera X Nexavar X oxaliplatin X Tarceva X Velcade X Xeloda X Source: NRDL List, China,

15 With cost of therapy a significant barrier, many branded oncology drugs face significant adoption lag Share for branded oncology products in China is generally lower than in the G7, even when limiting analysis to Tier 1 cities Even for agents that have identical indications globally and have been marketed for long duration (e.g., Rituxan), the share in China is significantly lower Only the newer EGFR TKIs (i.e., Tarceva and Iressa) have been adopted to a level nearly equal that observed in the G7 Use of Branded Targeted Therapies Globally 100.0% 80.0% 60.0% 40.0% 20.0% 0.0% Avastin in 1L mcrc Erbitux in 2L mcrc MabThera in 1L FL Herceptin in 1L BC Nexavar in 1L HCC China US EU5 Japan EGFR TKI in 1L EGFRmt NSCLC In general, only a proportionally small percentage of patients within the high income bracket will be able to afford highly priced innovative medicines Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians per tumor in three Tier 1 cities. 14

16 Key differences in the treatment of non-small cell lung cancer in China compared with the G7 The choice of modality for the treatment of NSCLC is largely consistent globally There is, however, significant variation in the choice of chemotherapy regimen in metastatic patients Lower priced generic regimens dominate in China, although Alimta is beginning to gain utilization in this treatment setting (increasing from 4% in 2011 to 22% in 2012), which may be due in part to the recent availability of Chinese generics on the market Treatment of 1L Non-squamous NSCLC, 2012 Japan EU5 US China 0% 20% 40% 60% 80% 100% platinum-gemcitabine platinum-docetaxel platinum-alimta platinum-paclitaxel platinum doublet + Avastin Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 16

17 Key differences in the treatment of non-small cell lung cancer in China compared with the G7, continued In the era of targeted therapy, NSCLC is the poster child for personalized medicine, with Tarceva and Iressa approved for the treatment of EGFR mutant patients and Xalkori approved for the treatment of ALK mutant patients In China, Conmana is also approved in EGFR mutants, and Xalkori is not yet launched Key to success of any biomarker-defined agent is the adoption of biomarker testing in patients EGFR mutation testing in NSCLC has increased slightly in recent years, but still only one-half of patients are tested for the mutation 80% EGFR Biomarker Testing, 1L NSCLC, China 60% 40% 20% 0% Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15, Survey of 50 physicians in three Tier 1 cities. 17

18 Patients in China are managed less aggressively, with fewer lines of therapy for metastatic disease Despite multiple approved options, which in many cancers is similar to approvals in the G7, Chinese patients often receive fewer lines of systemic therapy for advanced disease Stage IV Colorectal Cancer Stage IV Renal Cell Carcinoma Follicular Lymphoma 80.0% 80.0% 80.0% 60.0% 60.0% 60.0% 40.0% 40.0% 40.0% 20.0% 20.0% 20.0% 0.0% 2nd Line 3rd Line 0.0% 2nd Line 3rd Line 0.0% 2nd Line 3rd Line China US EU5 Japan Fewer lines of therapy may reflect fewer treatment options, but also inability to access available options or a preference for alternative therapies Source: Kantar Health / Draco, CancerMPact Treatment Architecture, accessed March 15,

19 Implications for development in China Understand the available patient population Despite the large population of China, lower diagnosis rates and patient access to care will significantly reduce the size of the available cancer patient population In general, urban cities (Tier 1) and Level 3 hospitals represent the vast majority of patients that are likely to seek treatment with new oncology agents While there is a large population of cancer patients in China, several factors (such as not being diagnosed or not having access to care) shrinks the actual potential patient pool for pharma. Population Diagnosed Access to Care 19

20 Implications for development in China Understand the available patient population Cost of therapy is a significant factor for drug adoption, with even wellestablished global standards of care capture only minimal share in China Herceptin, MabThera, and Avastin are examples of premium cost biologics that have not gained significant utilization in China Alternatively, drugs with Chinese generic alternatives (such as Xeloda) or those with well-designed Patient Assistance Programs (PAPs, such as Iressa) have been successful in gaining moderate-to-high utilization in China 20

21 Implications for development in China Understand the available patient population Cost of therapy is a significant factor for drug adoption, with even wellestablished global standards of care capturing only minimal share in China Divergent standards of care globally need to be understood fully, to guide China-specific clinical trials, physician education, and effective sales training Drug therapy may be significantly different in China than G7, but choice of modality treatment may also vary and can have a major impact on drug adoption 21

22 Implications for development in China Understand the available patient population Cost of therapy is a significant factor for drug adoption, with even wellestablished global standards of care capturing only minimal share in China Divergent standards of care globally need to be understood fully, to guide China-specific clinical trials, physician education, and effective sales training Biomarker testing for patient selection for targeted agents should be developed effectively Complex and/or expensive assays may meet with resistance if patients cannot afford the out-of-pocket costs or if the test is not reproducible across multiple hospitals Understanding the complexities and limitations of the Chinese oncology market is critical for commercial success of any new drug therapy 22

23 Implications for development in China Thank you! 23

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India

More information

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Pascal Soriot, Head of Strategic Marketing

Pascal Soriot, Head of Strategic Marketing Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage

More information

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017 Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

Citi Global Healthcare Conference

Citi Global Healthcare Conference Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

WhitePaper. Oncology: The Disease, the Dynamics and the Difficulties of Global Marketing Research

WhitePaper. Oncology: The Disease, the Dynamics and the Difficulties of Global Marketing Research WhitePaper Oncology: The Disease, the Dynamics and the Difficulties of Global Marketing Research Introduction The World Health Organisation estimates that the incidence of cancer could increase by 50%

More information

Pass the Buck: The New Face of Oncology Formulary Management

Pass the Buck: The New Face of Oncology Formulary Management Pass the Buck: The New Face of Oncology Formulary Management June 16, 2016 Agenda U.S. Oncology Market Trends Prescriber Incentive Pathway Overview Oncology TA Deep-Dive Non-Small Cell Lung Cancer Multiple

More information

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Gastric Cancer Drug Discoveries

Gastric Cancer Drug Discoveries Gastric Cancer Drug Discoveries what the future holds March 2011 World Leaders in Health Industry Analysis Market Analysis Market Analysis There is room for considerable change in the gastric cancer market

More information

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin

Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin Roche Positioning AVASTIN-based therapy as essential to treat cancer Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader This presentation contains certain forward-looking

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study

More information

NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS

NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS Dr Susan O Reilly MB, FRCPC, FRCPI National Director National Cancer Control Programme IMSN Networking for

More information

Oncology Therapeutics Market in India to 2018

Oncology Therapeutics Market in India to 2018 Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research

More information

National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer

National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Regulatory Considerations in Oncology Trials in China. Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi

Regulatory Considerations in Oncology Trials in China. Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi Regulatory Considerations in Oncology Trials in China Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi 1 Disclaimer The views and opinions provided are those of the speaker and do not reflect those of

More information

MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS

MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May

More information

What is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people*

What is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people* What is the Impact of Cancer on African Americans in Indiana? Table 13. Burden of Cancer among African Americans Indiana, 2008 2012 Average number of cases per year Rate per 100,000 people* Number of cases

More information

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017 HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda

More information

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject

More information

Realigning Reimbursement Policies for Quality and Value in Cancer Care

Realigning Reimbursement Policies for Quality and Value in Cancer Care Realigning Reimbursement Policies for Quality and Value in Cancer Care Jennifer Malin, MD, PhD Medical Director, Oncology Solutions and Innovation Pay for Performance Summit Mini-Summit V: Innovative Payment

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu. R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

Cancer Care Quality Program. Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015

Cancer Care Quality Program. Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015 Cancer Care Quality Program Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015 Off-Label Use Disclosure I do not intend to discuss an off-label use of a product during

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda

More information

European consortium study on the availability of anti-neoplastic medicines

European consortium study on the availability of anti-neoplastic medicines European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

Lipoplatin monotherapy for oncologists

Lipoplatin monotherapy for oncologists Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable

More information

ICLIO National Conference

ICLIO National Conference ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab) September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,

More information

Pharmaceutical market

Pharmaceutical market Pharmaceutical market I s P h a r m a a s i m p o r t a n t a s i t s e m p l o y e e s t h i n k? Our lives are getting longer In Europe, over the last 65 years, we have obeserved a significant increase

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

American Cancer Society Progress Report. December 2016

American Cancer Society Progress Report. December 2016 American Cancer Society Progress Report December 2016 2015 Goals Incidence: By 2015, 25% reduction (unlikely to meet goal) Baseline 1992-2013: 12.1% reduction Latest joinpoint trend: -1.5% APC (2009-2013)

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Pancreatic Cancer Market Research Report- Global Forecast till 2023

Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

2017 Community Oncology Alliance 1

2017 Community Oncology Alliance 1 2017 Community Oncology Alliance 1 The Value Of Community Oncology Lucio N. Gordan, MD Florida Cancer Specialists Director of Medical Informatics and Quality Disclosures American Oncology Network (AON)

More information

Media Release. Basel, 7 May 2018

Media Release. Basel, 7 May 2018 Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche

More information

Systemic Cytotoxic Therapy in advanced HCC

Systemic Cytotoxic Therapy in advanced HCC Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Media Release. Basel, 26 March 2018

Media Release. Basel, 26 March 2018 Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Cancer Facts & Figures for African Americans

Cancer Facts & Figures for African Americans Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases

More information

Trends in health care inflation & the cost of providing oncology treatment in South Africa (and a part of the solution)

Trends in health care inflation & the cost of providing oncology treatment in South Africa (and a part of the solution) Trends in health care inflation & the cost of providing oncology treatment in South Africa (and a part of the solution) Emile Stipp Chairman: IAAHS Chief Health Actuary: Discovery Session Number: TBR10

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

Immunotherapy in Oncology

Immunotherapy in Oncology Emerging Markets Market Access & Health Outcomes Immunotherapy in Oncology Comparing and contrasting payer and oncologist perspectives on the impact of a wave of immunotherapies (especially PD-1/PD-L1)

More information

Media Release. Basel, 07 December 2017

Media Release. Basel, 07 December 2017 Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Clinical Policy: (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The

More information

Evolution of Pathology

Evolution of Pathology 1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

China s Health Reform, Chronic Disease Burden and the Elderly

China s Health Reform, Chronic Disease Burden and the Elderly China s Health Reform, Chronic Disease Burden and the Elderly Shanlian Hu. MD. MSc. Professor School of Public Health Fu Dan University Aging Asia Workshop, Stanford Univ. February 26, 2009 1 Growth Trend

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER

THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER INTERNATIONAL HEALTH International health has been seen as

More information

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted

More information

For personal use only

For personal use only Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group

More information

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available

More information

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date: Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Cyramza. Cyramza (ramucirumab) Description

Cyramza. Cyramza (ramucirumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: September 15, 2017 Cyramza Description Cyramza

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information